// App-Quantinova.ai

: Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial

Researchers

Presenter

  • Klaus F. Rabe

Principal Investigators

  • Gary T Ferguson

  • Martin Jenkins

  • Mehul Patel

  • Paul Dorinsky

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

  • LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany,

  • Pulmonary Research Institute of Southeast Michigan, Farmingtin Hills, MI, United States.

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Seebri Breezhaler

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT02465567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved